BioSpace News Archive

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,370,415 covering the Company’s proprietary DNA and RNA binding technology.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2019, in Boston, MA,

Today Inversago Pharma Inc., a preclinical-stage biotech company developing novel CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of two seasoned pharma executives in line with the Company’s aim to attract first-class industry leaders for their guidance and expertise.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases and Gebro Pharma, a European mid-size Pharmaceutical company announced today it is holding an International Advisory Board conference with a panel of eleven Key Opinion Leaders in rheumatoid arthritis from Austria, Switzerland, and Spain focused on Piclidenoson.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2019 financial results.

Relmada Therapeutics Inc. announced that the Relmada team will ring the NASDAQ stock market opening bell tomorrow, Friday, October 18, 2019, at 9:30 AM ET, to commemorate the Company’s recent uplisting to the NASDAQ Capital Market.

NED Biosystems, a clinical-stage biotech company investigating solutions for a broad range of cancers, is pleased to announce Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRCPC, has been named Chairman of the Scientific Advisory Board.

Francis Medical, Inc. announced the appointment of Dr. Jonathan Jarow as the company’s chief medical officer Dr. Jarow will be leading Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.

Funded collaborative research effort strengthens the population simulation functionality in GastroPlus®

AMC Health, a leader in virtual healthcare delivery solutions, is pleased to announce the launch of its newly redesigned website at https://www.amchealth.com.